New mechanistic insights of integrin ß1 in breast cancer bone colonization

Oncotarget

Volumn 6, Issue 1, 2015, Pages 332-344

  Thibaudeau, Laure ^a   Taubenberger, Anna V ^a,b   Theodoropoulos, Christina ^a   Holzapfel, Boris M ^a,c   Ramuz, Olivier ^d   Straub, Melanie ^e   Hutmacher, Dietmar W ^a,f,g  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bone colonization; Breast cancer; Humanized bone models; 1 integrin; Tissue engineering

Indexed keywords

BETA1 INTEGRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; ANIMAL; BONE TUMOR; BREAST TUMOR; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TISSUE ENGINEERING; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTIGENS, CD29; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TISSUE ENGINEERING;

EID: 84921369186     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2788     Document Type: Article

References (44)

1. Australian Institute of Health and Welfare. (2012). Breast cancer in Australia: an overview. In: AIHW. C, ed. Cancer series no 71 (Canberra.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-1403.
3. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014; 64(1):9-29.
4. Clines GA and Guise TA. Mechanisms and treatment for bone metastases. Clinical advances in hematology & oncology: H&O. 2004; 2(5):295-302.
5. Buijs JT and van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Letters. 2009; 273(2):177-193.
6. Yoneda T and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochemical and Biophysical Research Communications. 2005; 328(3):679-687.
7. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE and Hall DMS. Molecular interactions in cancer cell metastasis. Acta Histochemica. 2010; 112(1):3-25.
8. Desgrosellier JS and Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10(1):9-22.
9. Marelli UK, Rechenmacher F, Sobahi TR, Mas-Moruno C and Kessler H. Tumor targeting via integrin ligands. Frontiers in oncology. 2013; 3:222.
10. Schneider JG, Amend SR and Weilbaecher KN. Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. Bone. 2011; 48(1):54-65.
11. White D and Muller W. Multifaceted roles of integrins in breast cancer metastasis. Journal of Mammary Gland Biology and Neoplasia. 2007; 12(2-3):135-142.
12. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U and Muller WJ. Targeted disruption of ß1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer cell. 2004; 6(2):159-170.
13. Lahlou H and Muller W. beta1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Research. 2011; 13(6):229.
14. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ and Bissell MJ. ß1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Research. 2006; 66(3):1526-1535.
15. Huck L, Pontier SM, Zuo DM and Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci U S A. 2010; 107(35):15559-15564.
16. Elliott BE, Ekblom P, Pross H, Niemann A and Rubin K. Anti-beta 1 integrin IgG inhibits pulmonary macrometastasis and the size of micrometastases from a murine mammary carcinoma. Cell Adhes Commun. 1994; 1(4):319-332.
17. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP and Rabbani SA. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006; 5(9):2271-2280.
18. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A and Mueller BM. Integrin activation controls metastasis in human breast cancer. Proceedings of the National Academy of Sciences. 2001; 98(4):1853-1858.
19. Sloan E, Pouliot N, Stanley K, Chia J, Moseley J, Hards D and Anderson R. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Research. 2006; 8(2):R20.
20. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P and Clezardin P. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007; 67(12):5821-5830.
21. Bretschi M, Merz M, Komljenovic D, Berger MR, Semmler W and Bauerle T. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep. 2011; 26(4):843-851.
22. Yang R-S, Tang C-H, Chuang W-J, Huang T-H, Peng H-C, Huang T-F and Fu W-M. Inhibition of tumor formation by snake venom disintegrin. Toxicon. 2005; 45(5):661-669.
23. Harms J, Welch D, Samant R, Shevde L, Miele M, Babu G, Goldberg S, Gilman V, Sosnowski D, Campo D, Gay C, Budgeon L, Mercer R, Jewell J, Mastro A, Donahue H, et al. A small molecule antagonist of the avß3 integrin suppresses MDA-MB-435 skeletal metastasis. Clinical and Experimental Metastasis. 2004; 21(2):119-128.
24. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D and Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007; 67(2):659-664.
25. dos Santos PB, Zanetti JS, Ribeiro-Silva A and Beltrao EI. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic pathology. 2012; 7:104.
26. Reichert JC, Quent VMC, Burke LJ, Stansfield SH, Clements JA and Hutmacher DW. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials. 2010; 31(31):7928-7936.
27. Taubenberger AV, Quent VM, Thibaudeau L, Clements JA and Hutmacher DW. Delineating breast cancer cell interactions with engineered bone microenvironments. J Bone Miner Res. 2013; 28(6):1399-1411.
28. Lundstrom A, Holmbom J, Lindqvist C and Nordstrom T. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun. 1998; 250(3):735-740.
29. Ibaragi S, Shimo T, Hassan NMM, Isowa S, Kurio N, Mandai H, Kodama S and Sasaki A. Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin α1ß1 and α2ß1-p38 MAPK signaling. Anticancer Res. 2011; 31(4):1307-1313.
30. Thibaudeau L, Taubenberger AV, Holzapfel BM, Quent VM, Fuehrmann T, Hesami P, Brown TD, Dalton PD, Power CA, Hollier BG and Hutmacher DW. A tissueengineered humanized xenograft model of human breast cancer metastasis to bone. Disease Models & Mechanisms. 2014; 7(2):299-309.
31. Hesami P, Holzapfel BM, Taubenberger A, Roudier M, Fazli L, Sieh S, Thibaudeau L, Gregory LS, Hutmacher DW and Clements JA. A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clin Exp Metastasis. 2014.
32. Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, Crawford R, Ling M-T, Clements JA, Russell PJ and Hutmacher DW. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials. 2014.
33. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. Journal of Bone and Mineral Research. 2001; 16(8):1486-1495.
34. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schlaepfer DD. FAK integrates growthfactor and integrin signals to promote cell migration. Nat Cell Biol. 2000; 2(5):249-256.
35. Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK, Liu K and Huang S. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Research. 2009; 69(24):9228-9235.
36. Provenzano PP, Inman DR, Eliceiri KW and Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAKERK linkage. Oncogene. 2009; 28(49):4326-4343.
37. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, Webster JD, Hoover S, Simpson RM, Gauldie J and Green JE. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010; 70(14):5706-5716.
38. Kusuma N, Denoyer D, Eble JA, Redvers RP, Parker BS, Pelzer R, Anderson RL and Pouliot N. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int J Cancer. 2012; 130(3):555-566.
39. Castello-Cros R, Khan D, Simons J, Valianou M and Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer. 2009; 9(1):94.
40. Shibue T and Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A. 2009; 106(25):10290-10295.
41. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA and Duong LT. Role of alpha(v) beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci. 1999; 112(Pt 22):3985-3993.
42. Barkan D and Chambers AF. ß1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clinical Cancer Research. 2011; 17(23):7219-7223.
43. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R, Berger J, Sewald N, Konig W and Backert S. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature. 2007; 449(7164):862-866.
44. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M and Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010; 12(4):27.